Managing the care of patients infected with bloodborne diseases

Journal of the American Dental Association

Volumn 134, Issue 3, 2003, Pages 350-358

  DePaola, Louis G ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b Pennsylvania Mid Atl AIDS Educ T   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPRENAVIR; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CLOTRIMAZOLE; DEXTROPROPOXYPHENE; FAMCICLOVIR; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; LOCAL ANESTHETIC AGENT; MIDAZOLAM; NYSTATIN; PETHIDINE; PIROXICAM; PSYCHOTROPIC AGENT; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VALACICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL TRANSMISSION; BLOODBORNE BACTERIUM; CANDIDA; CYTOMEGALOVIRUS; DATA ANALYSIS; DENTAL CARE; DENTAL HEALTH; DENTISTRY; DRUG CONTRAINDICATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; SAFETY; THRUSH; VARICELLA ZOSTER VIRUS; DRUG INTERACTION; GOVERNMENT REGULATION; METHODOLOGY; PRACTICE GUIDELINE;

BLOOD-BORNE PATHOGENS; DENTAL CARE FOR CHRONICALLY ILL; DRUG INTERACTIONS; GOVERNMENT REGULATION; GUIDELINE ADHERENCE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INFECTION CONTROL, DENTAL;

EID: 0038620091     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2003.0166     Document Type: Article

References (46)

1. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immune deficiency syndrome. MMWR Morb Mortal Wkly Rep 1999; 48(RR-13):1-28.
2. Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update: December 2002. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2002. Available at: "www.unaids.org/worldaidsday/ 2002/press/Epiupdate. html". Accessed Jan. 30, 2003.
3. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immune deficiency syndrome. MMWR Morb Mortal Wkly Rep 1999; 48(RR-13):1-28.
4. Centers for Disease Control and Prevention. Epidemiologic notes and reports immunodeficiency among female sexual partners of males with acquired immune deficiency syndrome (AIDS) - New York. MMWR Morb Mortal Wkly Rep 1983;31(52):697-8.
5. Bartlett JG. HIV: twenty years in review. Hopkins HIV Rep 2001;13(4):8-9.
6. Centers for Disease Control and Prevention. Acquired immunodeficiency syndrome (AIDS): precautions for health-care workers and allied professionals. MMWR Morb Mortal Wkly Rep 1983;32(34):450-1. Available at: "www.cdc.gov/ mmwr/preview/mmwrhtml/00000133. htm". Accessed Jan. 30, 2003.
7. Gallo RC, Sarip PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immunodeficiency syndrome (AIDS). Science 1983;220:865-7.
8. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
9. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990;322:941-9.
10. U.S. Food and Drug Administration. Approved drugs for HIV/AIDS and AIDS-related conditions. February 19, 2002. Available at: "www.fda.gov/ oashi/aids/stat_app.html". Accessed Jan. 30, 2003.
11. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
12. Sperling RS, Shapiro DE, Coombs RW, et al. The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335:1621-9.
13. Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update: December 2000. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2000.
14. Palella F, Delany K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
15. Mocroft A, Vella S, Benfiels T, et al. Changing patterns of mortality across Europe in patients with HIV-1. Euro SIDA Study Group. Lancet 1998;352(9142):1725-30.
16. Bartlett J, Gallant J. Medical management of HIV infection. 2001 ed. Baltimore: Johns Hopkins University, Department of Infectious Diseases; 2001.
17. Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents; Feb. 4, 2002. Available at: "www.aidsinfo.nih.gov/guidelines/adult\html_adult_02-04-02.html". Accessed Jan. 19, 2003.
18. U.S. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents; April 2001. Available at: "aidsinfo.nih.gov/guidelines/adult/archive/AA_042301/index.html". Accessed Jan. 19, 2003.
19. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
20. Echevarria K, Hardin T and Smith J. Hyperlipidaemia associated with protease inhibitor therapy. Ann Pharmacother 1999;33: 859-63.
21. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study. Circulation 1999;100:700-5.
22. Kaul D, Cinti S, Carver P, Kazanjian PH. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999;19:281-98.
23. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32(1): 130-9.
24. Carr A, Samaras K, Thorisdittir A, et al. Diagnosis, prediction and natural course of HIV-1-protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
25. Flynn T, Bricker L. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999;131:548.
26. Fauci A, Pantaleo G, Stanley S, et al. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124:654-63.
27. U.S. Department of Health and Human Services. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Available at: "www.aidsinfo.nih.gov/guidelines/ ". Accessed Jan. 19, 2003.
28. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001;344:159-67.
29. Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181(5):1635-42.
30. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy: eight European study groups. N Engl J Med 2001;344(3): 168-74.
31. Centers for Disease Control and Prevention. Summary of notifiable diseases in the United States, 1998. MMWR Morb Mortal Wkly Rep 1998;47(53):1-93.
32. Centers for Disease Control and Prevention. Viral hepatitis B: fact sheet. Available at: "www.cdc.gov/ncidod/diseases/hepatitis/b/ fact.htm". Accessed Jan. 30, 2003.
33. Liver disease. In: Little JW, Falace DA, Miller CS, et al., eds. Dental management of the medically compromised dental patient. 6th ed. St. Louis: Mosby; 2002:161-87.
34. Centers for Disease Control and Prevention (CDC). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47(No. RR-19):1-33.
35. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41-52.
36. National Institutes of Health. NIH Consensus Development Conference Statement: Management of hepatitis C-2002. Available at: "consensus.nih. gov/cons/116/Hepc091202.pdf". Acccessed Jan. 30, 2003.
37. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
38. Centers for Disease Control and Prevention. Recommended infection control practices for dentistry, 1993. MMWR Morb Mortal Wkly Rep 1993;42(RR-8):1-20.
39. Organization for Safety and Asepsis Procedures. Infection control guidelines: September, 1997. Available at: "www.osap.org/ resources/IC/icguide97.htm". Accessed Jan. 19, 2003.
40. ADA Council on Scientific Affairs and ADA Council on Dental Practice. Infection control recommendations for the dental office and the dental laboratory. Available at: "www.ada.org/prof/prac/ issues/topics/icontrol/ ic-recs/index.html". Accessed Jan. 19, 2003.
41. HIVDENT. Dental treatment considerations: treatment planning and ongoing care. Available at: "www.hivdent.org/dtctreatmen.htm". Accessed Jan. 19, 2003.
42. DePaola LG, ed. Dental management of the patient with HIV/AIDS: current concepts - 2002. Pittsburgh: Pennsylvania MidAtlantic AIDS Education and Training Center, HIV/AIDS Bureau, Health Resources and Services Administration, U.S. Department of Health and Human Services; 2002.
43. AIDS and related conditions. In: Little JW, Falace DA, Miller CS, et al., eds. Dental management of the medically compromised dental patient. 6th ed. St. Louis: Mosby; 2002:221-47.
44. Patton L, Glick M, Abel S, eds. Clinician's guide to HIV-infected patients. 3rd ed. Baltimore: American Academy of Oral Medicine Press; 2002.
45. The Dental Alliance for AIDS/HIV Care. Principles for the oral health management of the HIV/AIDS patient. Available at: "www.critpath.org/daac/ standards.html". Accessed Jan. 19, 2003.
46. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997;277(22):1794-801.